MARKET

GALT

GALT

Galectin Therapeutics Inc
NASDAQ
2.410
+0.040
+1.69%
Closed 16:00 03/27 EDT
OPEN
2.360
PREV CLOSE
2.370
HIGH
2.420
LOW
2.310
VOLUME
82.95K
TURNOVER
0
52 WEEK HIGH
2.480
52 WEEK LOW
1.280
MARKET CAP
149.06M
P/E (TTM)
-3.1586
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at GALT last week (0318-0322)?
Weekly Report · 3d ago
Galectin: Q4 2024 NASH Cirrhosis Data Readout Is A Major Inflection Point
Galectin Therapeutics is gearing up to report topline results from the phase 2b/3 NAVIGATE study in Q4 of 2024. The study is exploring the use of Belapectin for the prevention of esophageal varices in patients with NASH cirrhosis. Galectin has a major milestone approaching towards the end of 2024 with the release of data from the study.
Seeking Alpha · 03/21 00:11
Inventiva Phase 2 study for MASH drug meets primary endpoint
Inventiva Phase 2 study for MASH drug meets primary endpoint. Inventiva's drug candidate lanifibranor met its primary efficacy endpoint in the treatment of patients with MASH/NASH and type 2 diabetes. Last week, Madrigal drug Rezdiffra became the first FDA-approved treatment for the liver disorder.
Seeking Alpha · 03/18 21:45
Weekly Report: what happened at GALT last week (0311-0315)?
Weekly Report · 03/18 12:24
NASH drug market expected to surpass $48B by 2035
Healthcare NASH drug market expected to surpass $48B by 2035. Global therapeutic market catering to the widely prevalent liver disease non-alcoholic steatohepatitis is projected to reach $48.3B. North America is set to generate the lion's share of revenue. Europe is anticipated to record the highest CAGR in the NASH treatment market. Madrigal Pharmaceuticals received FDA approval for first U.S.-approved NASH therapy.
Seeking Alpha · 03/16 16:57
Madrigal climbs amid hopes for new NASH drug; B. Riley upgrades
FDA approves Madrigal Pharmaceuticals' new drug for nonalcoholic steatohepatitis. Rezdiffra is the first U.S.-approved therapy for NASH. B. Riley upgrades the company's stock to Neutral from Sell. The company's shares are up 26% in the premarket.
Seeking Alpha · 03/15 12:19
Madrigal granted FDA approval for NASH therapy
Madrigal Pharmaceuticals' lead asset resmetirom is the first U.S.-approved therapy for a liver condition called nonalcoholic steatohepatitis. The drug will be indicated with diet and exercise for NASH with moderate to advanced liver fibrosis. Madrigal granted FDA approval for NASh therapy for March 14, 2024.
Seeking Alpha · 03/14 19:45
Madrigal and liver drug developers fall ahead of FDA decision on NASH therapy
Madrigal and liver drug developers fall ahead of FDA decision on NASH therapy. Companies focused on developing drugs for a liver disease called nonalcoholic steatohepatitis are among the notable decliners. Madrigal Pharmaceuticals' lead asset, resmetirom, is targeted at NASH.
Seeking Alpha · 03/14 14:42
More
About GALT
Galectin Therapeutics Inc. is a clinical-stage biotechnology company. The Company is engaged in drug research and development to create new therapies for fibrotic disease, cancer and selected other diseases. The Company’s drug candidates are based on its method of targeting galectin proteins, which are key mediators of biologic and pathologic functions. The Company’s product candidates include galectin-3 inhibitor, which is a belapectin and GM-CT-01. The Company’s lead drug belapectin is a carbohydrate-based drug that inhibits the galectin-3 protein which is directly involved in multiple inflammatory, fibrotic, and malignant diseases. The Company is using a galectin-3 inhibitor to treat advanced liver fibrosis and liver cirrhosis in non-alcoholic steatohepatitis (NASH) patients. The Company also designed a Phase IIb/III clinical study, the NAVIGATE trial, evaluating the safety and efficacy of its galectin-3 inhibitor, belapectin, for the prevention of esophageal varices.

Webull offers Galectin Therapeutics Inc stock information, including NASDAQ: GALT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, GALT stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading GALT stock methods without spending real money on the virtual paper trading platform.